Skip to main content

Advertisement

Table 1 Characteristics of Patients Comparing IO-Chemotherapy with Chemotherapy in Included Trials

From: Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Source PD-(L)1 Drugb Histology No. of patientsa Median age (years)a Male (%)a Performance statusa PD-L1 subgroupsa
ITT As treated ECOG 0 (%) ECOG 1 (%) <1% (%) 1–49% (%) ≥50% (%)
KEYNOTE-189 2018 [6] Pembrolizumab nonsquamous 410 vs 206 405 vs 202 65 vs 64 62 vs 53 45 vs 39 54 vs 61 31 vs 31 31 vs 28 32 vs 34
IMpower150 2018 [15] Atezolizumab nonsquamous 400 vs 400 393 vs 394 63 vs 63 60 vs 60 39 vs 43 60 vs 57 47 vs 50 33 vs 31 20 vs 19
KEYNOTE-021 2016 [5], 2018 [20] Pembrolizumab nonsquamous 60 vs 63 59 vs 62 63 vs 63 37 vs 41 40 vs 46 58 vs 54 35 vs 37 32 vs 37 33 vs 27
KEYNOTE-407 2018 Pembrolizumab squamous 278 vs 281 278 vs 280 65 vs 65 79 vs 84 26 vs 32 74 vs 68 34 vs 35 37 vs 37 26 vs 26
IMpower131 2018 [17] Atezolizumab squamous 343 vs 340 334 vs 334 65 vs 65 81 vs 82 34 vs 32 66 vs 68 47 vs 50 38 vs 36 15 vs 14
CheckMate 227 2018 [18] Nivolumab suqamous and nonsquamous 177 vs 186 172 vs 185 64 vs 64 73 vs 67 33 vs 31 66 vs 68 100 vs 100 0 vs 0 0 vs 0
  1. aData presented as “IO-chemotherapy group vs chemotherapy group”
  2. bPembrolizumab (200 mg, Q3W), Atezolizumab (1200 mg, Q3W), Nivolumab (360 mg, Q3W)
  3. Abbreviation: IO immuno-oncology, ITT intention-to-treat